Cited 39 times in
Enhancement of Tumor-Specific T Cell-Mediated Immunity in Dendritic Cell-Based Vaccines by Mycobacterium tuberculosis Heat Shock Protein X
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신성재 | - |
dc.date.accessioned | 2015-01-06T17:09:09Z | - |
dc.date.available | 2015-01-06T17:09:09Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0022-1767 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/99434 | - |
dc.description.abstract | Despite the potential for stimulation of robust antitumor immunity by dendritic cells (DCs), clinical applications of DC-based immunotherapy are limited by the low potency in generating tumor Ag-specific T cell responses. Therefore, optimal conditions for generating potent immunostimulatory DCs that overcome tolerance and suppression are key factors in DC-based tumor immunotherapy. In this study, we demonstrate that use of the Mycobacterium tuberculosis heat shock protein X (HspX) as an immunoadjuvant in DC-based tumor immunotherapy has significant potential in therapeutics. In particular, the treatment aids the induction of tumor-reactive T cell responses, especially tumor-specific CTLs. The HspX protein induces DC maturation and proinflammatory cytokine production (TNF-α, IL-1β, IL-6, and IFN-β) through TLR4 binding partially mediated by both the MyD88 and the TRIF signaling pathways. We employed two models of tumor progression and metastasis to evaluate HspX-stimulated DCs in vivo. The administration of HspX-stimulated DCs increased the activation of naive T cells, effectively polarizing the CD4(+) and CD8(+) T cells to secrete IFN-γ, as well as enhanced the cytotoxicity of splenocytes against HPV-16 E7 (E7)-expressing TC-1 murine tumor cells in therapeutic experimental animals. Moreover, the metastatic capacity of B16-BL6 melanoma cancer cells toward the lungs was remarkably attenuated in mice that received HspX-stimulated DCs. In conclusion, the high therapeutic response rates with tumor-targeted Th1-type T cell immunity as a result of HspX-stimulated DCs in two models suggest that HspX harnesses the exquisite immunological power and specificity of DCs for the treatment of tumors. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.relation.isPartOf | JOURNAL OF IMMUNOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Antigens, Bacterial/administration & dosage* | - |
dc.subject.MESH | Antigens, Bacterial/immunology* | - |
dc.subject.MESH | Bacterial Proteins/administration & dosage* | - |
dc.subject.MESH | Bacterial Proteins/immunology* | - |
dc.subject.MESH | Cell Line, Transformed | - |
dc.subject.MESH | Cell Line, Tumor | - |
dc.subject.MESH | Dendritic Cells/immunology* | - |
dc.subject.MESH | Dendritic Cells/transplantation | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunity, Cellular | - |
dc.subject.MESH | Immunotherapy, Adoptive/methods* | - |
dc.subject.MESH | Lung Neoplasms/immunology | - |
dc.subject.MESH | Lung Neoplasms/secondary | - |
dc.subject.MESH | Lung Neoplasms/therapy | - |
dc.subject.MESH | Lymphocyte Activation/immunology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Melanoma, Experimental/immunology* | - |
dc.subject.MESH | Melanoma, Experimental/secondary | - |
dc.subject.MESH | Melanoma, Experimental/therapy* | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Mice, 129 Strain | - |
dc.subject.MESH | Mice, Inbred C57BL | - |
dc.subject.MESH | Mice, Knockout | - |
dc.subject.MESH | Mice, Transgenic | - |
dc.subject.MESH | Primary Cell Culture | - |
dc.subject.MESH | T-Lymphocytes, Cytotoxic/immunology* | - |
dc.subject.MESH | T-Lymphocytes, Cytotoxic/transplantation | - |
dc.subject.MESH | Up-Regulation/immunology* | - |
dc.title | Enhancement of Tumor-Specific T Cell-Mediated Immunity in Dendritic Cell-Based Vaccines by Mycobacterium tuberculosis Heat Shock Protein X | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | In Duk Jung | - |
dc.contributor.googleauthor | Sung Jae Shin | - |
dc.contributor.googleauthor | Min-Goo Lee | - |
dc.contributor.googleauthor | Tae Heung Kang | - |
dc.contributor.googleauthor | Hee Dong Han | - |
dc.contributor.googleauthor | Seung Jun Lee | - |
dc.contributor.googleauthor | Woo Sik Kim | - |
dc.contributor.googleauthor | Hong Min Kim | - |
dc.contributor.googleauthor | Won Sun Park | - |
dc.contributor.googleauthor | Han Wool Kim | - |
dc.contributor.googleauthor | Cheol-Heui Yun | - |
dc.contributor.googleauthor | Eun Kyung Lee | - |
dc.contributor.googleauthor | T.-C. Wu | - |
dc.contributor.googleauthor | Yeong-Min Park | - |
dc.identifier.doi | 10.4049/jimmunol.1400656 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02113 | - |
dc.relation.journalcode | J01450 | - |
dc.identifier.eissn | 1550-6606 | - |
dc.identifier.pmid | 24990079 | - |
dc.contributor.alternativeName | Shin, Sung Jae | - |
dc.contributor.affiliatedAuthor | Shin, Sung Jae | - |
dc.citation.volume | 193 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1233 | - |
dc.citation.endPage | 1245 | - |
dc.identifier.bibliographicCitation | JOURNAL OF IMMUNOLOGY, Vol.193(4) : 1233-1245, 2014 | - |
dc.identifier.rimsid | 39425 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.